Doctors in China Are Starting Human Trials for a Coronavirus Treatment

China has kick-started a clinical trial to speedily test a drug for the novel coronavirus infection as the nation rushes therapies for those afflicted and scours for vaccines to protect the rest. Remdesivir, a new antiviral drug by Gilead Sciences Inc. aimed at infectious diseases such Ebola and SARS, will be tested by a medical team from Beijing-based China-Japan Friendship Hospital for efficacy in treating the deadly new strain of coronavirus, a hospital spokeswoman told Bloomberg News Monday. Trial for the drug will be conducted in the central Chinese city of Wuhan — ground zero of the viral outbreak that has so far killed more than 360 people, sickened over 17,000 in China and spread to more than a dozen nations. As many as 270 patients with mild and moderate pneumonia caused by the virus will be recruited in a randomized, double-blinded and placebo-controlled study, Chinese news outlet The Paper reported on Sunday. Drugmakers such as GlaxoSmithKline Plc. as well as Chinese authorities are racing to crash develop vaccines and therapies to combat the new virus that’s more contagious than SARS and could cost the global economy four times more than the $40 billion sapped by the 2003 SARS outbreak. The decision to hold human trials for remdesivir shows it’s among the most promising therapies against the virus that so far has no specific treatments or vaccines. Experimental Drug The experimental drug has not yet been approved for use by any drug regulator in...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV Bloomberg onetime overnight Source Type: news

Related Links:

Publication date: May 2020Source: Membrane Technology, Volume 2020, Issue 5Author(s):
Source: Membrane Technology - Category: Materials Science Source Type: research
Publication date: May 2020Source: Membrane Technology, Volume 2020, Issue 5Author(s):
Source: Membrane Technology - Category: Materials Science Source Type: research
Conclusions: We first reported the effect of VDR gene FokI (rs2228570) polymorphism on the incidence of chronic spontaneous urticaria in the Chinese Han population. PMID: 32489362 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Authors: Nowicki RJ, Trzeciak M, Kaczmarski M, Wilkowska A, Czarnecka-Operacz M, Kowalewski C, Rudnicka L, Kulus M, Mastalerz-Migas A, Peregud-Pogorzelski J, Sokołowska-Wojdyło M, Śpiewak R, Adamski Z, Czuwara J, Kapińska-Mrowiecka M, Kaszuba A, Krasowska D, Kręcisz B, Narbutt J, Majewski S, Reich A, Samochocki Z, Szepietowski J, Woźniak K Abstract The treatment goal in atopic dermatitis is eliminating clinical symptoms of the disease, preventing exacerbations and complications, as well as improving patients' quality of life. In cases of severe atopic dermatitis and lack of response it is recommended to intro...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Publication date: Available online 3 June 2020Source: Clinica Chimica ActaAuthor(s): Agostino Ognibene, Maria Lorubbio, Pasqualino Magliocca, Emanuela Tripodo, Guendalina Vaggelli, Giovanni Iannelli, Marco Feri, Raffaele Scala, Alessandro Polcini Tartaglia, Angelo Galano, Alessandro Pancrazzi, Danilo Tacconi
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Publication date: Available online 4 June 2020Source: Obesity Research &Clinical PracticeAuthor(s): Diego Moriconi, Stefano Masi, Eleni Rebelos, Agostino Virdis, Maria Laura Manca, Salvatore De Marco, Stefano Taddei, Monica Nannipieri
Source: Obesity Research and Clinical Practice - Category: Eating Disorders & Weight Management Source Type: research
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
By ANISH KOKA, MD COVID is here. A little strand of RNA that used to live in bats has a new host.  And that strand is clearly not the flu.  New York is overrun, with more than half of the nation’s new cases per day, and refrigerated 18-wheelers parked outside hospitals serve as makeshift morgues.  Detroit, New Orleans, Miami, and Philadelphia await an inevitable surge of their own with bated breath.  America’s health care workers are scrambling to hold the line against a deluge of sick patients arriving hourly at a rate that’s hard to fathom.  I pause here to attest to the ...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: COVID-19 Health Policy Anish Koka coronavirus Pandemic Sars-CoV-2 WHO World Health Organization Source Type: blogs
This article is republished from The Conversation. Read the original article. The post Coronavirus: Ten Reasons Why You Ought Not to Panic appeared first on Inter Press Service. Excerpt: Ignacio López-Goñi is microbiologist and works in University of Navarra (Spain). The post Coronavirus: Ten Reasons Why You Ought Not to Panic appeared first on Inter Press Service.
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Global Headlines Health Coronavirus Source Type: news
It took eight hours for a doctor to see Wu Chen’s mother after she arrived at the hospital. Eight days later, she was dead. The doctor was “99% sure” she had contracted the mysterious pneumonia-like illness sweeping China’s central city of Wuhan, Wu says, but he didn’t have the testing kit to prove it. And despite the 64-year-old’s fever and perilously low oxygen levels, there was no bed for her. Wu tried two more hospitals over the next week, but all were overrun. By Jan. 25, her mother was slumped on the tile floor of an emergency room, gasping for air, drifting in and out of conscious...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV China Source Type: news
More News: China Health | Clinical Trials | Contracts | Coronavirus | COVID-19 | Ebola | Ebola Vaccine | Economy | Epidemics | Epidemiology | Health | Hospitals | Infectious Diseases | Japan Health | Kaletra | Outbreaks | Pneomococcal Vaccine | Pneumonia | SARS | Study | Vaccines